In 2024 and 2025 (1403–1404 in the Iranian calendar), several clinical evaluation projects were conducted at the Dermalab laboratory to assess the efficacy and safety of Iranian-manufactured botulinum toxin products (Botox) in comparison with an international reference drug (Dysport®).
Across these studies, an average of 150 participants with moderate to severe glabellar lines were enrolled and followed for four months after the initial injection.
At 30 days, preliminary results indicated that the efficacy of the Iranian products was comparable to that of Dysport®, producing a significant reduction in glabellar line severity in approximately 60% to 85% of participants.
Reported adverse events were mild and transient, supporting the favorable safety profile of the domestic formulations. All evaluations were performed using standardized digital facial photography.
